Evaluating Novel Therapies in ctDNA Positive GI Cancers
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility therapeutic trial. The study will enroll 20 patients across 4 cohorts (CRC, gastric, PDAC, and HCC/intra-hepatic-/extra-hepatic-, gall bladder adenocarcinomas) diagnosed with histologically confirmed GI cancers. These patients will have already completed all Standard of Care (SOC) treatments (including neoadjuvant, surgery, local therapies, and/or adjuvant therapy as applicable), as defined by the treating primary physician or research team, with curative intent but have a positive SignateraTM tumor-informed ctDNA test and NED radiographically by standard imaging within 28 days prior to enrollment and within 1 year of completing all curative-intent therapy. All patients will be treated with intravenous (IV) atezolizumab 1200 mg IV and bevacizumab 15 mg/kg on Day 1 of 21-day cycles until disease recurrence, ctDNA POD, unacceptable toxicity, or subject withdrawal of consent with a maximum 12 month total duration of study therapy. Atezolizumab and bevacizumab drug will be provided.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzona histologicznie diagnoza raka jelita grubego, żołądka, trzustki, wątroby lub dróg żółciowych
- •Ukończone całe standardowe leczenie zmierzające do wyleczenia (operacja, chemioterapia, radioterapia)
- •Brak widocznych śladów choroby w badaniach obrazowych (TK, rezonans) wykonanych maksymalnie 28 dni przed włączeniem
- •Pozytywny test ctDNA (Signaterra) świadczący o ryzyku nawrotu
- •Zdolność do uczestniczenia w badaniu i przyjmowania leków
- •Podpisana świadoma zgoda pacjenta
- •Dla pacjentów z rakiem wątroby: dobry stan wątroby (skala Child-Pugha A)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 14, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., United States
Medstar Washington Hospital Center
Washington D.C., United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, United States
Trial contact
Loyanna Hubbard
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.